The 'Most Potent Vasoconstrictor' Doesn't Seem to Drive Heart Failure

Researchers compared three groups: 13 healthy controls, 10 patients with moderate heart failure, and 11 with severe heart failure. They measured urotensin-II levels in blood drawn from four different locations in the cardiovascular system. They also checked gene expression of the urotensin-II precursor in heart tissue and blood vessels using RT-PCR. In severe heart failure patients who received vasodilator therapy, they tracked urotensin-II levels over 24 hours.

Urotensin-II had been identified as the most potent vasoconstrictor known, which made it a prime suspect in heart failure — a condition where blood vessels constrict too much and the heart can't keep up. This study provided early evidence that despite its powerful vasoconstrictor ability, urotensin-II doesn't appear to play a major role in human heart failure, redirecting research efforts toward other peptide targets.

This study is part of the broader effort to identify which vasoactive peptides actually contribute to heart failure. While urotensin-II's extreme potency as a vasoconstrictor made it a logical suspect, this negative finding helped narrow the field and redirect attention to other peptide systems like natriuretic peptides and endothelin that have proven more relevant to heart failure pathophysiology.

Small sample size (34 total participants). Single-center study. Only measured circulating levels and gene expression — did not assess receptor expression or local tissue activity. The 24-hour monitoring window may have been too short to capture slower changes.